These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8397255)

  • 1. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.
    Tilg H; Shapiro L; Atkins MB; Dinarello CA; Mier JW
    J Immunol; 1993 Sep; 151(6):3299-307. PubMed ID: 8397255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.
    Tilg H; Shapiro L; Vannier E; Poutsiaka DD; Trehu E; Atkins MB; Dinarello CA; Mier JW
    J Immunol; 1994 Mar; 152(6):3189-98. PubMed ID: 8144913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans.
    Bargetzi MJ; Lantz M; Smith CG; Torti FM; Olsson I; Eisenberg SP; Starnes HF
    Cancer Res; 1993 Sep; 53(17):4010-3. PubMed ID: 8395334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy.
    Tilg H; Atkins MB; Dinarello CA; Mier JW
    Cytokine; 1995 Oct; 7(7):734-9. PubMed ID: 8580384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
    Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
    Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors.
    Frishman JI; Edwards CK; Sonnenberg MG; Kohno T; Cohen AM; Dinarello CA
    J Infect Dis; 2000 Dec; 182(6):1722-30. PubMed ID: 11069245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
    Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
    J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro anti-inflammatory activity of Phlebodium decumanum. Modulation of tumor necrosis factor and soluble TNF receptors.
    Punzón C; Alcaide A; Fresno M
    Int Immunopharmacol; 2003 Sep; 3(9):1293-9. PubMed ID: 12890427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
    Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
    Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer.
    Kopp WC; Urba WJ; Rager HC; Alvord WG; Oppenheim JJ; Smith JW; Longo DL
    Clin Cancer Res; 1996 Mar; 2(3):501-6. PubMed ID: 9816196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergetic effect of dialyzer membrane and lipopolysaccharide on peripheral blood mononuclear cell cytokine production in uremic patients.
    Gu Y; Ding F; Qin H; Zhao H; Lin S
    Chin Med J (Engl); 2000 Apr; 113(4):315-9. PubMed ID: 11775226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes.
    Malyak M; Smith MF; Abel AA; Hance KR; Arend WP
    J Immunol; 1998 Aug; 161(4):2004-10. PubMed ID: 9712073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production.
    Tsuboi I; Tanaka H; Nakao M; Shichijo S; Itoh K
    Cytokine; 1995 May; 7(4):372-9. PubMed ID: 8589268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia.
    Calkins CM; Bensard DD; Shames BD; Pulido EJ; Abraham E; Fernandez N; Meng X; Dinarello CA; McIntyre RC
    J Endotoxin Res; 2002; 8(1):59-67. PubMed ID: 11981446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative cytokine and cytokine inhibitor production by mononuclear cells and neutrophils.
    Xing L; Remick DG
    Shock; 2003 Jul; 20(1):10-6. PubMed ID: 12813362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo.
    McKenzie RC; Oran A; Dinarello CA; Sauder DN
    Anticancer Res; 1996; 16(1):437-41. PubMed ID: 8615650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of interleukin-1 receptor antagonist (IL-1ra) and severity of illness in patients with burns.
    Endo S; Inada K; Yamada Y; Kasai T; Takakuwa T; Nakae H; Kamei Y; Shimamura T; Suzuki T; Taniguchi S; Yoshida M
    J Med; 1996; 27(1-2):57-71. PubMed ID: 8863178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.